
|Articles|February 1, 2003
Increased tear production: Restasis approval a milestone for dry eye
The FDA approval of cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan) Dec. 26 marked a landmark for ophthalmology. The eye drop therapy for moderate to severe keratoconjunctivitis sicca is unique in that it treats the inflammatory process that causes the condition, and not just its symptoms.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
OT Roundup ep. 1: ADHD's eye link, MOGENRY's BLA, and myopia news
2
Laru-zova meets primary endpoint in pivotal VISTA trial for X-linked retinitis pigmentosa
3
Addressing geographic variation in dry eye disease care requires patient-centric approaches
4
Geographic atrophy featured across EURETINA 2026 scientific programme
5











